Daily Endocrinology Research Analysis
Analyzed 35 papers and selected 3 impactful papers.
Summary
Today's most impactful endocrinology papers highlight: (1) GLP-1 receptor agonist use after breast cancer diagnosis in women with type 2 diabetes was associated with improved overall survival in a propensity-matched cohort; (2) In a head-to-head RCT subanalysis (SURMOUNT-5), tirzepatide achieved greater weight, BMI, and waist reductions than semaglutide among participants meeting Japan’s ‘obesity disease’ criteria; (3) In endoscopic nonfunctioning pituitary adenoma surgery, intraoperative MRI-guided additional resection increased gross total resection without higher risk of new endocrinological deficits.
Research Themes
- Metabolic-oncology interface: GLP-1RA and survival in breast cancer with type 2 diabetes
- Comparative anti-obesity pharmacotherapy: tirzepatide versus semaglutide
- Endoscopic pituitary surgery: intraoperative MRI and endocrine safety
Selected Articles
1. GLP-1 receptor agonist use and overall survival among women with type 2 diabetes and breast cancer: a retrospective cohort study.
In a propensity score–matched, single-institution cohort of 226 pairs of women with T2D and breast cancer, post-diagnosis GLP-1RA exposure was associated with lower all-cause mortality (HR 0.51) with consistent findings in stage I–III disease. Landmark and Kaplan-Meier analyses corroborated improved overall survival.
Impact: This study addresses the metabolic-oncology interface, suggesting GLP-1RA therapy may confer survival benefits beyond glycemic and weight control in T2D patients with breast cancer.
Clinical Implications: For women with T2D and breast cancer, GLP-1RAs may be reasonable options for metabolic management with potential survival benefit; multidisciplinary evaluation is warranted pending causal confirmation.
Key Findings
- GLP-1RA exposure after diagnosis was associated with lower all-cause mortality (HR 0.51, 95% CI 0.28–0.93).
- Sensitivity analysis in stage I–III patients showed similar benefit (HR 0.45, 95% CI 0.23–0.85).
- Kaplan–Meier curves demonstrated improved overall survival with GLP-1RA exposure (log-rank p=0.02).
Methodological Strengths
- Propensity score matching with multivariable Cox models and landmark analysis
- Sensitivity analysis by stage and survival visualization with Kaplan–Meier
Limitations
- Single-institution retrospective design with potential residual confounding
- All-cause mortality endpoint without cancer-specific cause-of-death adjudication
Future Directions: Prospective multicenter studies or pragmatic RCTs should test whether GLP-1RA initiation post-cancer diagnosis improves cause-specific and overall survival and evaluate safety in oncology settings.
BACKGROUND: Diabetes and obesity are associated with worse prognosis in women with breast cancer. However, the impact of glucagon-like peptide-1 receptor agonists (GLP-1RA) on survival following breast cancer diagnosis remains unclear. METHODS: We conducted a single institution, propensity-score matched, retrospective, 2-year landmark study of women with type 2 diabetes (T2D) diagnosed with breast cancer at City of Hope (2009-2025). Patients were categorized based on post-diagnosis exposure to GLP-1RA. Patients were compared across exposure groups using t-tests for continuous variables, chi-square tests for categorical variables, multivariable Cox proportional hazards models for overall mortality risk, and Kaplan-Meier plots for survival time. RESULTS: In 226 matched pairs, there were 47 deaths (30 in unexposed patients and 17 in exposed patients). GLP-1RA exposure was associated with a significantly lower risk of overall mortality (HR = 0.51, 95% CI 0.28-0.93, p = 0.03) on multivariable analysis. A sensitivity analysis in stage I-III patients yielded similar results (HR = 0.45, 95% CI 0.23-0.85, p = 0.03). Kaplan-Meier survival analysis also showed an association between increased overall survival and GLP-1RA exposure (log-rank p = 0.02). CONCLUSIONS: In this retrospective cohort of women with T2D and breast cancer, GLP-1RA use after diagnosis was associated with improved overall survival in T2D. These findings reflect all-cause mortality and do not distinguish between cancer-specific and non-cancer causes of death and should therefore be interpreted accordingly.
2. Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial.
In a SURMOUNT-5 subpopulation (n=383) meeting Japan Society for the Study of Obesity ‘obesity disease’ criteria, tirzepatide produced greater reductions in body weight, BMI, and waist circumference than semaglutide in head-to-head randomized treatment.
Impact: Direct head-to-head evidence in a criteria-relevant subpopulation informs payer and clinical decisions in Japan and supports generalizability of tirzepatide’s superiority for weight loss.
Clinical Implications: For patients meeting Japanese ‘obesity disease’ criteria, tirzepatide may be prioritized over semaglutide for greater anthropometric benefit, while individual tolerability and comorbidities should guide choice.
Key Findings
- Among 750 SURMOUNT-5 participants, 383 met Japan’s ‘obesity disease’ criteria and were analyzed.
- Tirzepatide yielded greater reductions in body weight, BMI, and waist circumference than semaglutide in this subpopulation.
- Findings align with overall head-to-head superiority signals for tirzepatide in chronic weight management.
Methodological Strengths
- Head-to-head randomized design within a predefined subpopulation
- Global trial with registration (NCT05822830), supporting protocolized assessments
Limitations
- Subpopulation analysis may be underpowered for safety endpoints and is hypothesis-generating
- Abstract lacks detailed safety outcomes and full numerical effect sizes
Future Directions: Full reporting of efficacy and safety in this subpopulation, cost-effectiveness analyses in Japan, and real-world comparative effectiveness studies are needed.
OBJECTIVE: To evaluate the efficacy and safety of tirzepatide versus semaglutide in individuals eligible for pharmacotherapy for obesity disease under Japan's national insurance criteria, where obesity is defined as body mass index (BMI) ≥25 kg/m METHODS: This subpopulation analysis of the SURMOUNT-5 trial (NCT05822830) included participants meeting obesity disease criteria: hypertension or dyslipidemia with BMI 27-35 kg/m RESULTS: Of 750 participants, 383 met the criteria for obesity disease (tirzepatide 15 mg or maximum tolerated dose [MTD], CONCLUSION: In this subpopulation analysis, tirzepatide was associated with greater reductions in weight, BMI, and waist circumference than semaglutide in individuals with obesity disease. STUDY REGISTRATION: ClinicalTrials.gov, NCT05822830. [Figure: see text].
3. Risk of new endocrinological deficits after intraoperative MRI-guided additional resection in endoscopic non-functioning pituitary adenoma surgery.
In 155 NFPA patients undergoing endoscopic transsphenoidal surgery with 3T ioMRI, additional resection was performed in 46%, increasing GTR from 35% to 65%, without an associated rise in new endocrinological deficits at discharge, 6 weeks, or final follow-up.
Impact: Provides safety evidence supporting ioMRI-guided extent-of-resection maximization without compromising pituitary endocrine function.
Clinical Implications: Surgeons can consider ioMRI-guided additional resection to improve GTR in NFPAs with reassurance about short- and medium-term endocrine safety; structured endocrine follow-up remains essential.
Key Findings
- Additional resection after 3T ioMRI was undertaken in 46% (71/155) and increased GTR from 35% intraoperatively to 65% at 3 months.
- New endocrinological deficits were 23% at discharge, 25% at 6 weeks, and 18% at final follow-up; additional resection was not associated with higher risk.
- Logistic regression showed no association of GTR, tumor volume, residual volume, or ioMRI-guided resection with new deficits.
Methodological Strengths
- Prospectively collected data with endocrinologist-adjudicated hormonal outcomes
- Multivariable regression to assess associations with new deficits
Limitations
- Retrospective analysis and single-center setting may limit external validity
- Minimum follow-up of 3 months; long-term endocrine outcomes beyond study period are unclear
Future Directions: Prospective multicenter registries and longer-term endocrine follow-up could refine patient selection and confirm durable safety and tumor control benefits.
OBJECTIVE: Intraoperative magnetic resonance imaging (ioMRI) has been increasingly used in transsphenoidal surgery for pituitary adenomas to improve the rate of gross total resection (GTR). However, its influence on postoperative pituitary function-particularly the risk of new endocrinological deficits (EDs) due to an additional resection-has not been investigated in detail. This study aimed to evaluate the endocrinological outcomes of ioMRI-guided TSS in patients with nonfunctioning pituitary adenomas (NFPAs), with a focus on the risk of new EDs following ioMRI-guided additional resection. METHODS: We performed a retrospective cohort analysis of prospectively collected data from 312 patients who underwent endoscopic transsphenoidal surgery with the "chopsticks" technique between July 2013 and July 2022. Of these, 155 patients met the inclusion criteria: histologically confirmed NFPA phenotype and 3-Tesla ioMRI usage. All patients had at least 3 months of endocrinological and MRI follow-up. Hormonal outcomes were reviewed by a dedicated endocrinologist using clinical and biochemical assessments. RESULTS: Among the 155 included patients (median age 60 years; 59% male), the ioMRI GTR rate was 35%; this increased to 65% (n = 98) on 3‑month postoperative MRI as a result of ioMRI‑guided additional resection. Overall, additional resection following ioMRI was performed in 46% (n = 71) of cases. New EDs of at least one pituitary axis were observed in 23% (n = 35) of patients at discharge, 25% (n = 38) at first follow-up (6 weeks postoperatively), and 18% (n = 28) at final follow-up in total. Any recovery of preoperative EDs occurred in 9.7%, 31% and 45% respectively. Uni- and multivariate logistic regression analysis showed that neither GTR, tumor volume, residual tumor volume nor additional resection following ioMRI were associated with increased risk of new deficits. CONCLUSIONS: IoMRI-guided additional resection during TSS for NFPAs can be performed safely without increasing the risk of new EDs. These findings support the utility of ioMRI in maximizing the extent of resection while preserving pituitary function.